<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521361</url>
  </required_header>
  <id_info>
    <org_study_id>20511</org_study_id>
    <secondary_id>2019-000475-17</secondary_id>
    <nct_id>NCT04521361</nct_id>
  </id_info>
  <brief_title>A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the Bones</brief_title>
  <official_title>Open-label, Non-randomized Phase 1, Multicenter Study to Assess Radium- 223 Biodistribution in Participants With Bone Metastatic Castration Resistant Prostate Cancer (CRPC) Receiving Radium-223 Dichloride Treatment.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study researcher want to gain more information on how the study drug (radium-223) is&#xD;
      distributed in the bone, particularly in the tumor free bone in participants with prostate&#xD;
      cancer. The study plans to enroll 60 patients with the age of at least 18 years and suffering&#xD;
      from prostate cancer which has spread to the bones. Researcher will divide the study&#xD;
      participants into 2 groups. Patients in Group 1 should have up to 6 bone metastases and&#xD;
      patients for group 2 should have more than 6 bone metastases. The study medication will be&#xD;
      given as injection into a vein every 4 weeks up to a maximum of 6 times. To study how radium&#xD;
      distributes in the body and particularly in the bones, participants will undergo after study&#xD;
      medication intake MRI or CT Scans (imaging techniques).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">June 22, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 25, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC of radium-223 in tumor-free bone after 3 doses</measure>
    <time_frame>At 4, 24 and 144 hours post injection at Cycle 3 ( total duration of one cycle is 28 days).</time_frame>
    <description>The uptake of radium-223 in bone is determined with single-photon emission tomography / computed tomography (SPECT/CT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC of radium-223 in tumor-free bone after single dose</measure>
    <time_frame>At 4, 24 and 144 hours post injection at Cycle 1 ( total duration of one cycle is 28 days).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of radium-223 in tumor-free bone after 6 doses</measure>
    <time_frame>At 4, 24 and 144 hours post injection at Cycle 6 ( total duration of one cycle is 28 days).</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Bone Metastatic Castration-resistant Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Patients with Low extent of disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult men with bone mCRPC having &lt; 6 bone metastases</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with High extent of disease</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult men with bone mCRPC having ≥ 6 bone metastases</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Radium-223 dichloride (Xofigo, BAY88-8223)</intervention_name>
    <description>Drug will be administered as aqueous solution intravenously at a dose of 55 kBq/kg body weight every 4 weeks for 6 cycles (cycle length = 4 weeks).</description>
    <arm_group_label>Patients with High extent of disease</arm_group_label>
    <arm_group_label>Patients with Low extent of disease</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants who have histologically confirmed adenocarcinoma of the prostate.&#xD;
&#xD;
          -  Participants with bone metastatic CRPC, progressing after 1 or 2 prior lines of&#xD;
             systemic treatment for metastatic prostate cancer (including prior treatment for&#xD;
             metastatic hormone sensitive prostate mHSPC or metastatic castration resistant&#xD;
             prostate cancer mCRPC).&#xD;
&#xD;
          -  Participants with at least 2 bone metastases on Tc 99m phosphonate whole body planar&#xD;
             bone scans at Screening.&#xD;
&#xD;
          -  Documented progression of mCRPC. Disease progression is defined by at least one of the&#xD;
             following criteria: a. PCWG3 criteria (defined as 2 consecutive increases in PSA over&#xD;
             a previous reference value measured at least one week prior, with a minimal start&#xD;
             value of 1.0 ng/mL) or b. ≥2 new bone lesions (according to PCWG3 bone scan criteria)&#xD;
             or c. Radiological progression according to RECIST, version 1.1.&#xD;
&#xD;
          -  Ability to participate in the required study procedures including all scanning&#xD;
             procedures and ability to control pain to ensure tolerance and completion of the&#xD;
             necessary scanning procedures.&#xD;
&#xD;
          -  Maintenance of medical castration or surgical castration with testosterone less than&#xD;
             50 ng/dL (1.7 nmol/L). If the participant is being treated with luteinizing hormone&#xD;
             releasing hormone (LHRH) agonists or antagonists (participant who has not undergone&#xD;
             orchiectomy), this therapy must have been initiated at least 4 weeks prior to start of&#xD;
             Screening and must be continued throughout the study.&#xD;
&#xD;
          -  Participants must be on a bone health agent prior to the first dose of radium-223&#xD;
             dichloride. Participants with at least 6 months of prior bone health agent (BHA)&#xD;
             treatment are preferred.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1.&#xD;
&#xD;
          -  Life expectancy ≥6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any chronic medical condition requiring continuous systemic corticosteroid treatment&#xD;
             at a higher dose than 5 mg prednisone / prednisolone twice daily.&#xD;
&#xD;
          -  Pathological finding consistent with neuroendocrine features small cell carcinoma of&#xD;
             the prostate.&#xD;
&#xD;
          -  Metastatic bone deposits extend of disease (EOD) grades 0 or 4 (according to centrally&#xD;
             assessed Tc 99m phosphonate planar bone scans during Screening).&#xD;
&#xD;
          -  History of visceral metastasis, or presence of visceral metastasis detected by&#xD;
             screening imaging examinations (according to central review at screening).&#xD;
&#xD;
          -  Other malignancy treated within the last 5 years (except non-melanoma skin cancer or&#xD;
             low-grade superficial bladder cancer).&#xD;
&#xD;
          -  Imminent spinal cord compression based on clinical findings and / or magnetic&#xD;
             resonance imaging (MRI). - Participants with history of spinal cord compression should&#xD;
             have completely recovered.&#xD;
&#xD;
          -  Active or symptomatic viral hepatitis&#xD;
&#xD;
          -  Inability to tolerate any of the other imaging procedures in the study (ie, bone&#xD;
             SPECT/CT and planar bone scans with a Tc 99m phosphonate radiotracer, DXA scan,&#xD;
             radium-223 SPECT/CT scans).&#xD;
&#xD;
          -  Any condition, which in the opinion of the investigator would preclude participation&#xD;
             in this trial.&#xD;
&#xD;
          -  Hypersensitivity to radium-223 dichloride.&#xD;
&#xD;
          -  Blood transfusion or erythropoietin stimulating agents 4 weeks prior to start of&#xD;
             Screening and during the whole Screening period before enrollment into the cohort.&#xD;
&#xD;
          -  Prior administration of an investigational therapeutic for CRPC.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <phone>(+)1-888-84 22937</phone>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ordensklinikum Linz GmbH Elisabethinen</name>
      <address>
        <city>Linz</city>
        <state>Oberösterreich</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Uniklinikum Salzburg - Landeskrankenhaus</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>HUS, Meilahden sairaala</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut du Cancer de Montpellier - Val d'Aurelle</name>
      <address>
        <city>Montpellier Cedex</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie de l'Ouest - Saint Herblain</name>
      <address>
        <city>Saint Herblain</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud - iUCT Oncopole</name>
      <address>
        <city>Toulouse Cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Münster (UKM)</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Rambam Health Corporation</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>AUSL-IRCCS di Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <state>Emilia-Romagna</state>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08660</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santaros Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Trust (Surrey)</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University College London Hospitals NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>NW1 2PG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guy's and St. Thomas' NHS Trust, St. Thomas' Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>October 25, 2021</last_update_submitted>
  <last_update_submitted_qc>October 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic castration-resistant prostate cancer (mCRPC)</keyword>
  <keyword>Single-photon emission tomography / computed tomography (SPECT/CT)</keyword>
  <keyword>radium-223,</keyword>
  <keyword>phase I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Radium Ra 223 dichloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Availability of this study's data will be determined according to Bayer's commitment to the EFPIA/PhRMA &quot;Principles for responsible clinical trial data sharing&quot;. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

